Ken Valenzano

All filings by Ken Valenzano on record concern Amicus Therapeutics, Inc. In total, 31 filings cover trades dated from 24 May 2011 to 13 July 2015.

On the open market, the record shows 6 purchases worth €246k and 14 sales worth €1.1M. The net balance comes to €879k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants and 9 option exercises. In 2015 alone, the filings show no purchases and 10 sales.

A typical purchase (the median) is worth €33k.

The latest filing, published on 15 July 2015, reports an open-market sale of €130k in Amicus Therapeutics, Inc. The most recent open-market purchase was published on 25 November 2014, 4,367 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.